zealand
pharma
hosts
conference
call
november
pm
cet
et
present
third
quarter
results
press
release
zealand
pharma
hosts
conference
call
november
pm
cet
et
present
third
quarter
results
copenhagen
dk
november
zealand
pharma
nasdaq
zeal
announced
host
conference
call
november
pm
cet
et
following
announcement
results
third
quarter
presenting
call
president
chief
executive
officer
emmanuel
dulac
senior
vice
president
chief
financial
officer
matt
dallas
executive
vice
president
chief
medical
officer
adam
steensberg
presentation
followed
q
session
conference
call
conducted
english
numbers
denmark
copenhagen
united
kingdom
united
states
france
paris
netherlands
amsterdam
confirmation
code
live
audio
webcast
call
including
accompanying
slide
presentation
available
via
following
link
https
mmc
p
accessible
investor
section
zealand
website
investor
due
increased
demand
conference
call
services
could
take
longer
connected
call
participants
advised
register
webcast
minutes
scheduled
start
possible
recording
event
transcript
available
investor
section
zealand
website
call
zealand
pharma
zealand
pharma
nasdaq
zeal
zealand
biotechnology
company
focused
discovery
development
commercialization
innovative
medicines
drug
candidates
invented
zealand
advanced
clinical
development
two
reached
market
zealand
robust
pipeline
investigational
medicines
includes
three
candidates
late
stage
development
one
candidate
reviewed
regulatory
approval
united
states
zealand
markets
insulin
delivery
option
people
diabetes
license
collaborations
boehringer
ingelheim
alexion
pharmaceuticals
create
opportunity
patients
potentially
benefit
peptide
therapeutics
zealand
founded
copenhagen
denmark
presence
throughout
includes
key
locations
new
york
boston
marlborough
information
zealand
business
activities
please
visit
statement
information
contains
statements
provide
zealand
pharma
expectations
forecasts
future
events
statements
subject
risks
uncertainties
inaccurate
assumptions
may
cause
actual
results
differ
materially
expectations
set
forth
herein
may
cause
statements
incorrect
statements
prove
incorrect
actual
results
could
differ
materially
adversely
anticipated
implied
statements
statements
speak
date
release
based
information
available
zealand
pharma
date
release
information
please
contact
mads
kronborg
head
investor
relations
communication
phone
email
mkronborg
